Active — Not RecruitingNot Applicable

TTM-Based Social Media Psychoeducation for Psychosis

Turkey (Türkiye)60 participantsStarted 2025-03-01

Plain-language summary

This doctoral research investigates the effect of a Transtheoretical Model (TTM)-based psychoeducation program delivered via social media on treatment adherence in individuals diagnosed with psychosis. The study follows a randomized controlled trial design with pretest, posttest, and three-month follow-up assessments. A total of 60 participants were selected from among 354 individuals registered at the Balıkesir Community Mental Health Center (CMHC), based on predefined inclusion and exclusion criteria. Participants were randomly assigned into three groups: 1. an online intervention group receiving a 5-week TTM-based treatment adherence psychoeducation program via WhatsApp; 2. a face-to-face intervention group receiving a standard, non-TTM-based treatment adherence psychoeducation program over 3 weeks at the CMHC; and 3. a control group that received no educational intervention, only assessments. Data collection instruments include a Sociodemographic Information Form, the Stage of Change Identification Form, the Medication Adherence Report Scale (MARS-5), and the Clinical Global Impression-Severity Scale (CGI-S). Measurements were conducted at baseline, post-intervention, and three months after the intervention. The study hypotheses are: Research Hypotheses H1: The treatment adherence scale scores of individuals diagnosed with psychosis who participate in the TTM-based psychoeducation group administered via social media will differ compared to the scores of individuals who participate in the face-to-face treatment adherence psychoeducation group. H2: The treatment adherence scale scores of individuals diagnosed with psychosis who participate in the TTM-based psychoeducation group administered via social media will differ compared to the scores of individuals who do not receive TTM-based psychoeducation. This study aims to provide evidence for the efficacy of theory-based, technology-supported psychoeducation programs in enhancing treatment adherence among individuals with psychosis. Furthermore, it evaluates whether a model-based online psychoeducation program is more effective than a conventional treatment adherence education.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 18 and 65 years * Diagnosed with a psychotic disorder according to DSM-5 criteria, including: * Schizophrenia * Schizophreniform disorder * Schizoaffective disorder (with mild mood symptoms) * Brief psychotic disorder * Substance/medication-induced psychotic disorder (in remission) * Paranoid disorder * On the same prescribed psychiatric medication for at least one month * Able to communicate in Turkish * Has access to the internet and owns at least one active social media account (Instagram, Twitter, Facebook, WhatsApp, etc.) * Literate and able to complete self-report forms * Willing to participate and provide informed consent * Clinical Global Impression-Severity (CGI-S) score of 4 or below Exclusion Criteria: * Under 18 or over 65 years of age * Acute psychotic episode at the time of recruitment * Comorbid psychiatric diagnoses not covered under the inclusion list * Diagnosed with neurocognitive disorders (e.g., dementia) * Diagnosed with intellectual disability (mental retardation) * Unable to use smartphone, tablet, or other digital communication tools * Missed more than 20% of the intervention sessions

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Medication Adherence (Treatment adherence)

Timeframe: Baseline (Week 0) and Post-Intervention (Week 5)

Change in Medication Adherence Scores (MARS-5)

Timeframe: Baseline, Post-Intervention (Week 5), and 3-Month Follow-Up

Trial details

NCT IDNCT07080827

SponsorIstanbul University - Cerrahpasa

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-01

View on ClinicalTrials.gov More Treatment Compliance trials